Apatinib Combined With Oral Etoposide in Metastatic HER2 Negative Breast Cancer
Status:
Completed
Trial end date:
2019-05-01
Target enrollment:
Participant gender:
Summary
The hypothesis of this study is to discover if the all-oral therapy with apatinib plus oral
Etoposide can shrink or slow the growth of pretreated HER2 negative metastatic breast cancer.